male reproductive cancers

BPH?

PSA?

Treat the ____ prostate.

____ cell patients do better than adeno.

AFP?

hockey stick shape field is always ____?

Prostate
testicular
penile/urethra     
how common??

Incidence of prostate ca:
____ although there appears to be some ____ relationship.
Often found concurrently w/ ____ ____ ____.

Penile/male urethra incidence:
Higher in ?
Penile ca is related to ____ ____?
Urethral ca is linked to chronic ____ and infections, ____, ____ diseases, and stictures.

Testicular cancers are rare, but ____ common ____ in men ages 20-34. Incidence is higer in males w/ ____ ____. (cryptoorchidism) Most common in ____ from the US, UK, and Denmark.

Pathology:
prostate- ____ is most common.
penile lesions- well differentiated ____ ____.
urethral lesions-well to moderately   differentiated ____ ____.
prostatic urethral lesions- ____ ____.
bulbomembranous urethral lesions-____.
testicular- 95% ____ cell. (seminoma 35-50%)

TURP?

Most common age:
prostate-
penile/urethra-
testicular-

XRT doses:PROSTATE
nodal doses?
seminal vesicle?
prostate?

XRT dose for penile/urethra ____Gy?
include ____ nodes.

XRT dose: TESTES
seminoma- ____cGy for stage I and stage IIA, boost of ____ -____cGy for stage IIA and higher.
nonseminoma (____) RT has ____ role in these tumors, except ____ of brain or other mets areas.

Histology: PROSTATE
Cancer is ____ and developes in the ____ of the prostate. Benign is ____. ____ invasion is ____ is most ____ cases.

Detection and Diagnoses: PROSTATE
(7) CCCDPMT

____ is used for staging prostate ca.

Prostate ca is the most common ____ in men. _:_ will develope in their lifetime. ____ ____ have one of the highest ____ in the world and a worse ____. Incresed risk in ____, Sweden, and ____. Decreased risk in ____, Taiwan, and ____ ____. Overall a slow growing malignancy.

Prognostic factors for prostate ca? (4) (TRPL)

As prostate ca grows, it may ____ into and through the ____ , invade ____ tissue, ____ vesicales and eventually the ____ or ____.

Treatment techniques for prostate ca?
____ for patients over 75. ____ T1 or T2 stage disease and life expectancy of at least 10 years. ____ ____ regresses prostate tumor. ____ mostly used for mets disease. ____ ____ positively charged particles deliver dose. (Bragg's peak)

Hormonal therapy examples? (4)

Testes routes/sites of spread.
seminoma: ____ to lymph nodes of ____, mediastinal, and ____ nodes. Only ____ stage disease spread hematogenously to the ____, bone, ____ or brain.

Testes:
nonseminomas- metastasize outside the ____ ____ involving lungs and ____.

Prostate major sites of spread are ____ and ____ ____. Blood goes to the ____, liver, and ____. Lymph nodes spread first to ____ and ____ nodes, followed by external ____, hypo gastric, common iliac, and ____ ____.